Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 2194-0042-23				SERIAL NO. NEW APPLICATI S N		
			APPLICANT			09/			
LIST OF	REFEF	RENCES CITED BY APPL	LICANT		Gwyn A. CUTSFOR				
			FILING DATE	FILING DATE HEREWITH 8/27/01		/ GROUP	GROUP 266		
				U.S. PATENT D	OCUMENTS				0 C O
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLAS	SS SUB CLASS		FILING DATE APPROPRIATE
i	AA								
	АВ								
	AC							<u> </u>	
	AD								
L'	AE	<u> </u>							
'	AF	<u> </u>							
<u>'</u>	AG	↓							
 	AH		 					 	
[!]	AI		 					 	
	AJ	 	 					+	
 	AK	 	 					+	
 	AL	 	 	+				+	
 	AN		-	+				+	
 	ر ختک	<u></u>		L DATENT					
		DOCUMENT	r	DREIGN PATENT	······································			TDANS	SLATION
	<u> </u>	NUMBER	DATE	<u> </u>	COUNTRY		YE		NO
<u> </u>	AO	<u> </u>							
 '	AP		 						
ļ	AQ								<u> </u>
	AR								
	AS AT			 					
 	AU		 	 		 -			
 	AU	 						\longrightarrow	<u> </u>
 		OTHER REE		** I A Lithi	Title Date B				ļ
<u> </u>				(Including Author				the of Th	Dutch
126-	AW	A. BROEKMANS, et al., "Congenital Protein C Defifciency and Venous Thromboembolism, A Study of Three Dutch Families", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 309, No. 6, pp. 340-344, 1983.							
76	AX	J. GRIFFIN, et al., "Protein C, an Antithrombotic Protein, Is Reduced in Hospitalized Patients with Intravascular Coagulation", BLOOD, Vol. 60, No. 1 (July), pp. 261-264, 1982.							
RO	AY	R. MARLAR, et al., "Serial Studies of Protein C and Its Plasma Inhibitor in Patients with Disseminated Intravascular Coagulation", BLOOD, Vol. 66, No. 1 (July), pp. 59-63, 1985.							
726-	AZ	"Protein C in the Treatment of coagulopathy in meningococcal disease", THE LANCET, Vol. 347, page 1767, June 1996.							
Examiner		RG UTOMEN Date Considered 5/3/02							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in									

1

		PATENT AND TRADEMARK OFFICE	2194-0042-23	SERIAL NO. NEW APPLICATION				
LIST OF F	REFER	RENCES CITED BY APPLICANT	APPLICANT Gwyn A CL	JTSFORTH, et al.				
			FILING DATE	GROUP				
		OTHER REFERENCES (HEREWITH	4 Pares (44)				
			Including Author, Title, Date, Pertinen					
16	AAA	O. P. SMITH, et al., "Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans", THE LANCET, Vol. 350, pp. 1590-1593, November 1997.						
	AAB	R. FAVIER, et al., "Simultaneous administration of antithrombin III and protein C concentrates for the treatment of a devastating coagulopathy in a child", HEMATOL. CELL THER., Vol. 40, pp. 67-70, 1998.						
	AAC	J. PARKINSON, et al., "Stable Expre Mammalian Cells", THE JOURNAL C	ession of a Secretable Deletion Mutant of DF BIOLOGICAL CHEMISTRY, Vol. 265,	Recombinant Human Thrombomodulin in . , No. 21, pp. 12602-12610, July 1990.				
B. GERLITZ, et al., "Identification of the predominant glycosaminoglycan-attachment site in soluble recombined thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine 174", BIOCH 295, pp. 131-140, 1993.								
	AAE	D. T. BERG, et al., "High-Level Expression of Secreted Protein's form Cells Adapted to Serum-Free Suspension Culture", BIOTECHNIQUES, Vol. 14, No. 6, pp. 972-978, 1993.						
	AAF	J. PARKINSON, et al., "STRUCTURE-FUNCTION STUDIES OF THE EPIDERMAL GROWTH FACTOR DOMAINS OF HUMAN THROMBOMODULIN", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 185, No. 2, pp. 567-576, 1992.						
	AAG		pression, purification and characterization in the state of the state	n of small fragments of thrombomodulin: the Vol. 8, No. 11, pp. 1177-1187, 1995.				
	ААН			ble thrombomodulin from human urine", EUR.				
	AAI	S. M. RICHARDS, et al., "Quantitativ Human Protein C", CLIN. CHEM. Vol		Determination of Zymogen and Activated				
	AAJ		Soluble Forms of Thrombomodulin Inhib itor", J. BIOL. CHEM., Vol. 273, No. 5, 19	it Fibrinolysis by Potentiating The Activation o 998. ABSTRACT ONLY				
	AAK			, ARTERIOSCLER., THROMB., VASC. BIOL.,				
	AAL		coagulant activity of the mutant seine pro /ol. 6, No. 1, 1997. ABSTRACT ONLY	otease Ser360Ala-activated protein C mediated				
	S. YU, et al., "Construction, Expression, and Properties of a Recombinant chimeric Human Protein C with Replacement Its Growth Factor-like Domains by those of Human Coagulation Factor IX", BIOCHEMISTRY, Vol. 33, No. 3, 1994. ABSTRACT ONLY							
	AAN	C. L. ORTHNER, et al., "A sensitive a THROMB. HAEMOSTASIS, Vol. 69,		activated protein C activity levels in vivo",				
	AAO	K. G. MANN, et al., "Active site-speci	ific immunoassays", BLOOD, Vol. 76, No	o. 4, 1990. ABSTRACT ONLY				
	AAP	K. F. STOCKER, et al., "Snake prote	in C activator, methods of preparation ar	nd use thereof', US Patent. ABSTRACT ONLY				
	AAQ	S. NAKAMURA, et al., "Assay metho ABSTRACT ONLY	KAMURA, et al., "Assay methods for protein C (and protein S)", RINSHO BYORI, RINJI ZOKAN, Vol. 70, 1987, RACT ONLY					
Examiner		R Giromen		Date Considered 5/3/22				

SHEET 3 OF 3

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 2194-0042-23	SERIAL NO. NEW APPLICATION		
LIST OF REF	ERENCES CITED BY APPLICANT	APPLICANT Gwyn A. CUTSFORTH, et al.			
		FILING DATE HEREWITH	GROUP (627		
	OTHER REFERENCES ((Including Author, Title, Date, Pertinen			
- //	G. A. SOFF, et al., "Protein C levels	in nephrotic syndrome: use of a new enz	tyme-linked immunoadsorbent assay for		
R BB	A protein C antigen", AM. J. HEMATOL	L., Vol. 22, No. 1, 1986. ABSTRACT ON	ILY		
Ro BBI	R. M. BERTINA, et al., "The use of a heterogeneity of congenital protein C	functional and immunologic assay for pl deficiency", THROB. HAEMOSTASIS, N	asma protein C in the study of the Vol. 51, No. 1, 1984. ABSTRACT ONLY		
BBG	٥,				
ВВС					
ВВЕ	=				
ВВ	=				
вво	3				
ВВН	1				
ВВІ					
BBJ	1				
ввк	(
BBL					
BBM	1				
BBN	ı				
ВВО	,				
ВВР					
BBQ					
Examiner	Giromen		Date Considered 5/3/02		

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.